Kolesnyk, Pavlo O.
Paliy, Iryna H.
Sydorchuk, Larysa P.
Hoda, Zoriana P.
Ivanchenko, Nataliya O.
Lych, Oksana S.
Huley, Natalia R.
Matsyura, Oksana I.
Slyuzar, Zoryana L.
Gerasymov, Sergiy V.
Funding for this research was provided by:
Nordic Biotic Sp. z o.o. (# DT0003A-COV, # DT0003A-COV, # DT0003A-COV, # DT0003A-COV, # DT0003A-COV, # DT0003A-COV, # DT0003A-COV)
Article History
Received: 10 July 2023
Accepted: 22 December 2023
First Online: 4 January 2024
Declarations
:
: Approvals were obtained from ethical committees at all study sites (Lviv Oblast Center for Disease Control and Prevention Ministry of Health of Ukraine, protocol #2 of 20 Apr 2021; Lviv Municipal Non-Profit Enterprise Third City Clinical Hospital, protocol #1 of 03 Jun 2021; Hemo Medica Clinic, protocol #2 of 09 Jun 2021; Vinnytsia Municipal Non-Profit Enterprise Center of Primary Health Care №2, protocol #24 of 18 Jan 2022; Chernivtsi Municipal Non-Profit Enterprise City Polyclinic №1, protocol #2 of 24 Jan 2022.The study was conducted in accordance with the principles of the Declaration of Helsinki and the privacy rights of patients were respected in compliance with Good Clinical Practices throughout the study. Before enrollment in the study, eligible participants had protocol-specific health insurance and were familiarized with the study procedures. A signed informed consent was obtained from all patients. This study was registered at ClinicalTrials.gov on July 01, 2021 before the first patient signed the informed consent form (identifier: NCT04907877).
: Not applicable.
: POK, IHP, LPS, ZРH, OSL, NRH received investigator fees; SVG received study management fee from Nordic Biotic Sp. z o.o. (Warsaw, Poland). NOI, OIM, ZLS reported no competing interests.